Li Dan, Jiang Sheng-Fang, Lei Nan Ye, Shah Shailja C, Corley Douglas A
Department of Gastroenterology, Kaiser Permanente Northern California, Santa Clara, California; Division of Research, Kaiser Permanente Northern California, Oakland, California.
Division of Research, Kaiser Permanente Northern California, Oakland, California.
Gastroenterology. 2023 Aug;165(2):391-401.e2. doi: 10.1053/j.gastro.2023.04.026. Epub 2023 May 2.
BACKGROUND & AIMS: High-quality data regarding the effect of Helicobacter pylori eradication on the risk of noncardia gastric adenocarcinoma (NCGA) remain limited in the United States. We investigated the incidence of NCGA after H pylori eradication therapy in a large, community-based US population.
We performed a retrospective cohort study of Kaiser Permanente Northern California members who underwent testing and/or treatment for H pylori between 1997 and 2015 and were followed through December 31, 2018. The risk of NCGA was evaluated using the Fine-Gray subdistribution hazard model and standardized incidence ratios.
Among 716,567 individuals with a history of H pylori testing and/or treatment, the adjusted subdistribution hazard ratios and 95% confidence intervals of NCGA for H pylori-positive/untreated and H pylori-positive/treated individuals were 6.07 (4.20-8.76) and 2.68 (1.86-3.86), respectively, compared with H pylori-negative individuals. When compared directly with H pylori-positive/untreated individuals, subdistribution hazard ratios for NCGA in H pylori-positive/treated were 0.95 (0.47-1.92) at <8 years and 0.37 (0.14-0.97) ≥8 years of follow-up. Compared with the Kaiser Permanente Northern California general population, standardized incidence ratios (95% confidence interval) of NCGA steadily decreased after H pylori treatment: 2.00 (1.79-2.24) ≥1 year, 1.01 (0.85-1.19) ≥4 years, 0.68 (0.54-0.85) ≥7 years, and 0.51 (0.38-0.68) ≥10 years.
In a large, diverse, community-based population, H pylori eradication therapy was associated with a significantly reduced incidence of NCGA after 8 years compared with no treatment. The risk among treated individuals became lower than the general population after 7 to 10 years of follow-up. The findings support the potential for substantial gastric cancer prevention in the United States through H pylori eradication.
在美国,关于幽门螺杆菌根除对非贲门部胃腺癌(NCGA)风险影响的高质量数据仍然有限。我们调查了在美国一个大型社区人群中,幽门螺杆菌根除治疗后NCGA的发病率。
我们对1997年至2015年间接受幽门螺杆菌检测和/或治疗且随访至2018年12月31日的北加利福尼亚州凯撒医疗集团成员进行了一项回顾性队列研究。使用Fine-Gray亚分布风险模型和标准化发病率评估NCGA的风险。
在716,567名有幽门螺杆菌检测和/或治疗史的个体中,与幽门螺杆菌阴性个体相比,幽门螺杆菌阳性/未治疗个体和幽门螺杆菌阳性/已治疗个体的NCGA调整后亚分布风险比及95%置信区间分别为6.07(4.20 - 8.76)和2.68(1.86 - 3.86)。与幽门螺杆菌阳性/未治疗个体直接比较时,在随访<8年时,幽门螺杆菌阳性/已治疗个体的NCGA亚分布风险比为0.95(0.47 - 1.92),随访≥8年时为0.37(0.14 - 0.97)。与北加利福尼亚州凯撒医疗集团的普通人群相比,幽门螺杆菌治疗后NCGA的标准化发病率(95%置信区间)稳步下降:随访≥1年时为2.00(1.79 - 2.24),≥4年时为1.01(0.85 - 1.19),≥7年时为0.68(0.54 - 0.85),≥10年时为0.51(0.38 - 0.68)。
在一个大型、多样化的社区人群中,与未治疗相比,幽门螺杆菌根除治疗与8年后NCGA发病率显著降低相关。随访7至10年后,接受治疗个体的风险低于普通人群。这些发现支持了在美国通过根除幽门螺杆菌实现大幅预防胃癌的可能性。